Form 4: Inotiv Inc. Executive Andrea Castetter Reports Stock Option Grant

Andrea Castetter, SVP, Gen. Counsel & Secretary of Inotiv, Inc., reports the acquisition of stock options.

Summary

• On February 21, 2025, Andrea Castetter, SVP, Gen. Counsel & Secretary of Inotiv, Inc., acquired 6,500 employee stock options with an exercise price of $4.205.
• The options vest over three years: 40% on February 21, 2026, 30% on February 21, 2027, and 30% on February 21, 2028, contingent upon continued employment.
• The options expire on February 21, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is neither particularly positive nor negative on its own.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Industry Context

Stock option grants are a common form of executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical services industries. They are used to attract and retain talent, and to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Charles River Laboratories and Envigo (now part of Inotiv) also utilize stock options as part of their compensation strategy.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns executive interests with shareholder value.

Key Dates